Meyer Colin John
- SEC CIK
- 0001662392
No open-market purchases or sales filed in the past year.
Current role at each company
- RETA Reata Pharmaceuticals IncChief Innovation Officeras of Sep 26, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Meyer Colin John as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 17, 2023 (view filing) | Aug 15-16 | 2 days | Meyer Colin JohnChief Innovation Officer | SSaleClass A common stock | −2.74K | $169.00 | −$463.1K | −3.2%81.6K after | 2 lots |
| May 17, 2023 (view filing) | May 15-16 | 2 days | Meyer Colin JohnChief Innovation Officer | SSaleClass A common stock | −6.23K | $84.56 | −$527.1K | −7.4%78.4K after | 3 lots |
| Mar 8, 2023 (view filing) | Mar 7 | 1 day | Meyer Colin JohnChief Innovation Officer | SSaleClass A common stock | −621 | $84.57 | −$52.5K | −0.7%84.6K after | |
| Mar 6, 2023 (view filing) | Mar 2-3 | 4 days | Meyer Colin JohnChief Innovation Officer | SSaleClass A common stock | −93.9K | $86.72 | −$8.15M | −52.4%85.2K after | 6 lots |